Keystone Biotech Consulting partners with companies to build meaningful, right-sized CMC strategies and reliable supply chains, giving your program the confidence to advance without unnecessary complexity.
We help biotech companies build the CMC infrastructure and supply chain discipline they need — without the overhead designed for commercial-stage programs.
We craft stage-appropriate CMC plans that align with your clinical objectives and regulatory milestones. From IND-enabling studies through Phase III, we define what matters now — and what can wait — so your team moves efficiently without unnecessary risk.
Regulatory success starts with documentation that is complete, coherent, and calibrated to your stage. We provide hands-on support navigating the CMC regulatory landscape — translating your program's data into clear, submission-ready packages that tell a compelling story to agencies.
We build a clear, comprehensive picture of your supply chain — CDMOs, raw material suppliers, testing labs, and logistics partners. Understanding dependencies and risks before they become problems is the foundation of a reliable clinical supply program.
We establish reliable, streamlined processes to support your clinical milestones. From demand forecasting and material release workflows to batch records and deviation management — we implement the right level of rigor without bureaucratic burden.
Early-stage biotech doesn't need big-pharma CMC infrastructure. It needs clear thinking, experienced judgment, and processes proportional to the program's current stage and risk profile.
We've seen what happens when young companies over-build CMC systems — and when they under-build them. Our role is to find the right balance: the keystone that holds everything together without collapsing under its own weight.
Each modality brings distinct CMC and supply chain challenges. We bring hands-on experience across all of them.
Monoclonal antibodies, fusion proteins, recombinant enzymes. Full CMC coverage from cell bank establishment to clinical vial release.
Antibody-drug conjugates demand integrated management of two complex supply chains — coordinated CMC and supply strategy for both biologic and small molecule components.
Bispecific antibodies introduce unique manufacturing and analytical complexity. We support format selection, process development strategy, and characterization planning.
Cell therapies, gene therapies, mRNA platforms, and emerging formats. Adaptive CMC frameworks suited to the unique requirements of novel therapeutic classes.
Whether you're building your first CMC plan or untangling a supply chain that's grown too complicated, we're here to help. Let's start with a conversation.